E.U. Expands Antitrust Review Of Guidant Deal

Law360, New York (March 27, 2006, 12:00 AM EST) -- As feared by industry observers, the European Commission chose Monday to expand its antitrust inquiry into the long-awaited acquisition of medical device maker Guidant Corp. by rival Boston Scientific Corp.

The delay will cost Boston Scientific tens of millions of dollars. The company had held out hopes of completing the deal by March 30, but conceded that might change after the company made certain commitments to the Commission last week.

The commitments were intended to alleviate the Commission's antitrust concerns.

The Commission’s announcement has pushed the...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.